The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Current and next generation influenza vaccines: Formulation and production strategies
Open accessAbstract
Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304459 · Cited by 2,310
Emergence and pandemic potential of swine-origin H1N1 influenza virus
Neumann, G., Noda, T., & Kawaoka, Y. (2009) · Nature · doi:10.1038/nature08157 · Cited by 1,561
Wilkinson, T. M., Li, C. K. F., Chui, C. S. C., Huang, A. K. Y., Perkins, M., Liebner, J. C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2612 · Cited by 974
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 885
Cellular immune correlates of protection against symptomatic pandemic influenza
Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T., Barclay, W., Deeks, J. J., & Lalvani, A. (2013) · Nature Medicine · doi:10.1038/nm.3350 · Cited by 862
Large-scale manufacture of peptide therapeutics by chemical synthesis
Bray, B. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1133 · Cited by 598
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface
Lamb, R. A., Zebedee, S. L., & Richardson, C. D. (1985) · Cell · doi:10.1016/0092-8674(85)90211-9 · Cited by 576
Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain
Steel, J., Lowen, A. C., Wang, T. T., Yondola, M., Gao, Q., Haye, K., García-Sastre, A., & Palese, P. (2010) · mBio · doi:10.1128/mbio.00018-10 · Cited by 533
Kunisaki, K. M., & Janoff, E. N. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70175-6 · Cited by 516
de Jong, J. C., Claas, E. C. J., Osterhaus, A. D. M. E., Webster, R. G., & Lim, W. L. (1997) · Nature · doi:10.1038/39218 · Cited by 497
Cited by
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Understanding modern-day vaccines: what you need to know
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1407035 · Cited by 354
Next-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Biological sex affects vaccine efficacy and protection against influenza in mice
Fink, A. L., Engle, K., Ursin, R. L., Tang, W.-Y., & Klein, S. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805268115 · Cited by 253
Metadata
- Authors
- Soema, P. C., Kompier, R., Amorij, J.-P., & Kersten, G. F. A.
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 94
- Pages
- 251-263
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W591557396
- Cited by
- 314
- References
- 123
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and next generation influenza vaccines: Formulation and production strategies. https://app.cochat.ai/papers/10.1016/j.ejpb.2015.05.023
- The paper
- Soema, P. C., Kompier, R., Amorij, J.-P., & Kersten, G. F. A. (2015). Current and next generation influenza vaccines: Formulation and production strategies. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2015.05.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.